

# Miquel Baquero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5679392/publications.pdf>

Version: 2024-02-01

17  
papers

1,400  
citations

759233

12  
h-index

888059

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1502  
citing authors

#	ARTICLE	IF	CITATIONS
1	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
2	Plasma isoprostanoïds assessment as Alzheimer's disease progression biomarkers. <i>Journal of Neurochemistry</i> , 2021, 157, 2187-2194.	3.9	8
3	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
4	Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis. <i>Antioxidants</i> , 2021, 10, 1043.	5.1	13
5	Assessment of Screening Approach in Early and Differential Alzheimer's Disease Diagnosis. <i>Antioxidants</i> , 2021, 10, 1662.	5.1	2
6	Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer's Disease Differential Diagnosis. <i>Antioxidants</i> , 2020, 9, 649.	5.1	11
7	Isoprostanoïds Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer's Disease. <i>Antioxidants</i> , 2020, 9, 407.	5.1	4
8	Lipid peroxidation in neurodegeneration. <i>Clinica Chimica Acta</i> , 2019, 497, 178-188.	1.1	62
9	New screening approach for Alzheimer's disease risk assessment from urine lipid peroxidation compounds. <i>Scientific Reports</i> , 2019, 9, 14244.	3.3	25
10	Free radicals in Alzheimer's disease: Lipid peroxidation biomarkers. <i>Clinica Chimica Acta</i> , 2019, 491, 85-90.	1.1	96
11	Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker. <i>Journal of Proteomics</i> , 2019, 200, 144-152.	2.4	50
12	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 79, 131-141.	3.1	23
13	Validated analytical method to determine new salivary lipid peroxidation compounds as potential neurodegenerative biomarkers. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 742-749.	2.8	21
14	Reliable determination of new lipid peroxidation compounds as potential early Alzheimer Disease biomarkers. <i>Talanta</i> , 2018, 184, 193-201.	5.5	44
15	Plasma lipid peroxidation biomarkers for early and non-invasive Alzheimer Disease detection. <i>Free Radical Biology and Medicine</i> , 2018, 124, 388-394.	2.9	51
16	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 85.	6.2	69
17	Potential oxidative stress biomarkers of mild cognitive impairment due to Alzheimer disease. <i>Journal of the Neurological Sciences</i> , 2017, 373, 295-302.	0.6	81